Secukinumab

Secukinumab, as an anti-interleukin-17A monoclonal antibody, usually used for treatment with the ankylosing spondylitis^[1].

In vitro experiment it indicated that when IL-17A at 956.2 ng/mL, secukinumab was obviously less potent^[2].

In vivo clinical trail it suggested that treatment with 150 mg secukinumab subcutaneously or intravenously in patients remarkedly reduced the signs and symptoms of ankylosing spondylitis at week 16. While treatment with 75 mg secukinumab subcutaneously caused obvious improvement only with a higher intravenous loading dose.^[1] Secukinumab has a highly favorable safety profile. In clinical test it demonstrated that treatment with 300 mg secukinumab, for occurs at a rate of 3.55/100 subject-years of mucocutaneous candidiasis, these infections usually do not interfere with maintenance of secukinumab therapy. Thus, secukinumab has an effictive new treatment for individuals with moderate-to-severe psoriasis.^[3] In pivotal phase III trials, at dose of 75–150 mg and 75–300 mg secukinumab subcutaneously in pediatric patients aged 6 to < 18 years, there is an markedly improvemnet compared with placebo. It is suggested that secukinumab improved health-related quality of life and was generally well tolerated. ^[4] In efficacy trail it indicated that in received subcutaneous secukinumab 150 mg with (LD) or without (NL) loading dose patients or placebo weekly, secukinumab significantly improved the signs and symptoms of nr-axSpA across patients grouped by C-reactive protein (+/−) and/or magnetic resonance imaging (+/−) status, HLA-B27 (+/−) status, and sex^[5].

References:
[1]Baeten D, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015 Dec 24;373(26):2534-48.
[2]Adams R, et al. Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F. Front Immunol. 2020 Aug 21;11:1894.
[3]Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf. 2016 Oct;15(10):1413-20.
[4]Blair HA. Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis. Paediatr Drugs. 2021 Nov;23(6):601-608.
[5]Braun J, et al. Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT. Arthritis Res Ther. 2021 Sep 4;23(1):231.